VIP vasoactive intestinal peptide
Selected indexed studies
- Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF. (Front Endocrinol (Lausanne), 2024) [PMID:38774232]
- Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery. (Adv Protein Chem Struct Biol, 2015) [PMID:25819279]
- Vasoactive intestinal peptide (VIP), a putative neurotransmitter of nonadrenergic, noncholinergic (NANC) inhibitory innervation and its relevance to therapy. (J Vet Pharmacol Ther, 1989) [PMID:2568497]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF. (2024) pubmed
- Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery. (2015) pubmed
- Vasoactive intestinal peptide (VIP), a putative neurotransmitter of nonadrenergic, noncholinergic (NANC) inhibitory innervation and its relevance to therapy. (1989) pubmed
- Editorial: vasoactive intestinal peptide (vip): historic perspective and future potential. (2012) pubmed
- A new neuroregulator: the vasoactive intestinal peptide or VIP. (1982) pubmed
- Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes. (2022) pubmed
- Immunobiology of vasoactive intestinal peptide (VIP). (2000) pubmed
- Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. (2008) pubmed
- Vasoactive intestinal peptide (VIP): an amnestic neuropeptide. (1990) pubmed
- Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' disease. (2020) pubmed